Skip to content

Candel Therapeutics

US · CADL #3461 by market cap Listed 2021
9.57 -0.26 -2.60%
Live - 5344 symbols - heartbeat 492s ago · 2026-10-08 10:00
Pre-market 9.82 -0.02%
After-hours 9.83 +0.10%
Market cap
731.90M
P/B
5.80
EPS
-0.72
Reader sentiment Are you bullish or bearish on CADL?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 5.96 Expensive vs history 86th percentile
5-year average 1.96 · #398 of 513 in Biotechnology
P/E ratio -6.68 Cheap vs history 25th percentile
5-year average -4.55 · forward -7.33
P/S ratio 24,239.11 Expensive vs history 96th percentile
5-year average 6,275.12 · forward 302.99 · #381 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Candel Therapeutics (CADL) 731.90M -6.51 5.80 0.00%
Vertex Pharmaceuticals (VRTX) 128.41B 29.51 6.34 0.00%
Moderna (MRNA) 78.42B -24.61 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 75.37B 18.12 2.38 0.50%
argenx SE (ARGX) 51.17B 31.00 6.08 0.00%
Revolution Medicines (RVMD) 40.35B -21.22 15.48 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value10.07 Economic moatNone UncertaintyVery High

Trading 5.3% below Morningstar's fair value estimate.

Fair value

Candel Therapeutics Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% discount to our quantitative fair value estimate of $10.07 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet bolsters our estimated fair value. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 16.1 sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.8, a core component of valuation, ranks in the bottom 20% compared with global peers. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 10:00:27 · For reference only, not investment advice and not tailored to your situation.